Trastuzumab

DBCAT005586Pharmacologic classL01FD01

A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed. A DrugBank category of 2 drugs. 1 of them is approved.

ATC classification: L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 — ANTINEOPLASTIC AGENTS
L01F — MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FD — HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
L01FD01 — trastuzumab
Drugs: Lorvotuzumab mertansine
Trastuzumab emtansine

What you can answer from here — as of January 13, 2022

2DrugsEach linked to its full drug card

Listed above

2Drug targetsEvery drug–target pair in the class, with bond type

14Marketed productsAcross the regions we cover, with dosage forms and routes

2Routes of administrationHow the drugs in this class are given

Which targets do Trastuzumab share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account